Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Stock Position Decreased by Centiva Capital LP

Centiva Capital LP trimmed its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 72.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,465 shares of the company's stock after selling 17,110 shares during the period. Centiva Capital LP's holdings in Amphastar Pharmaceuticals were worth $314,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. TD Asset Management Inc increased its stake in Amphastar Pharmaceuticals by 67.4% in the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock valued at $67,663,000 after purchasing an additional 680,976 shares during the last quarter. Boston Trust Walden Corp purchased a new stake in Amphastar Pharmaceuticals in the 3rd quarter valued at about $26,189,000. Millennium Management LLC increased its stake in shares of Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after acquiring an additional 338,653 shares during the last quarter. Epoch Investment Partners Inc. increased its stake in shares of Amphastar Pharmaceuticals by 35.1% during the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock valued at $43,154,000 after acquiring an additional 280,390 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter worth approximately $9,085,000. 65.09% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the transaction, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. This represents a 6.51 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO William J. Peters sold 7,426 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $386,523.30. Following the transaction, the chief financial officer now owns 94,103 shares in the company, valued at $4,898,061.15. This trade represents a 7.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 34,533 shares of company stock valued at $1,676,542 in the last quarter. Company insiders own 27.10% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently commented on AMPH. StockNews.com downgraded Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a report on Friday, November 22nd. They issued an "equal weight" rating and a $55.00 price target on the stock. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus target price of $60.33.

Amphastar Pharmaceuticals Stock Down 0.2 %

Shares of AMPH stock traded down $0.07 during trading hours on Wednesday, reaching $43.57. The company had a trading volume of 328,155 shares, compared to its average volume of 399,011. The stock's fifty day simple moving average is $47.26 and its 200 day simple moving average is $44.62. The company has a market capitalization of $2.09 billion, a P/E ratio of 14.52, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a twelve month low of $36.56 and a twelve month high of $65.92.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.